Pacific Biosciences of California (PACB) ended the recent trading session at $1.18, demonstrating a +1.72% change from the ...

Volta Labs, a genomics applications company, today announced the launch of its Library Prep App for Oxford Nanopore LSK114 on ...

A research team has identified two novel genetic mechanisms for disease resistance in wheat, offering promising strategies to ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) announced better-than-expected revenue in Q1 CY2025, but ...

PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Pacific Biosciences of California faces steep stock decline and financial challenges. Click here to see why PACB stock is a ...

Castle Biosciences, Inc. (NASDAQ:CSTL) has announced new data to be presented at ASCO 2025 showing that its DecisionDx-Melanoma test is linked to a 32% reduction in mortality risk for patients ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) has announced the launch of its latest innovation, the Cytek Aurora Evo system, marking a significant leap forward in flow cytometry technology. Building on ...

Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Pacific Biosciences of California (PACB) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most ...

The use of cutting-edge genomic tools and technologies, including DNA sequencing, molecular markers, and bioinformatics, empowers researchers to accelerate the breeding process, reduce breeding cycles ...